SCHEMBL33530528

SCHEMBL33530528

CC1c2cc(N3CCC4(CCN(C(=O)OC(C)(C)C)CC4)C3)ccc2CCN1C(=O)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.41
CYP11B2 P19099 1/20 0.39
NR1H2 P55055 1/20 0.39
ESR2 Q92731 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
GPR119 Q8TDV5 7/20 0.37
CYP3A4 P08684 3/20 0.36
HSD17B10 Q99714 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC1 Q13547 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HIF1A Q16665 2/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
RET P07949 1/20 0.36
ACACB O00763 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33532485 0.96 CYP11B2 (0.41) PDK2CYP11B2NR1H2ESR2CYP3A4
SCHEMBL33533406 0.95 CYP11B2 (0.43) PDK2CYP11B2NR1H2ESR2GPR119
SCHEMBL33531973 0.80 CYP11B2 (0.43) CYP11B2GPR119HDAC2HDAC1ALDH1A1
SCHEMBL33530693 0.78 PDK2 (0.44) PDK2NR1H2ESR2NPC1RAB9A
SCHEMBL33533432 0.78 CYP11B2 (0.40) CYP11B2GPR119CYP3A4HSD17B10HDAC2
SCHEMBL33532144 0.77 CYP11B2 (0.41) PDK2CYP11B2GPR119CYP3A4ALDH1A1
SCHEMBL23412056 0.76 CYP11B2 (0.48) PDK2CYP11B2GPR119CYP3A4HSD17B10
SCHEMBL29933258 0.76 CYP11B2 (0.48) PDK2CYP11B2GPR119CYP3A4HSD17B10
SCHEMBL33532834 0.76 CYP11B2 (0.44) CYP11B2GPR119CYP3A4HDAC2HDAC1
SCHEMBL33533519 0.76 MEN1 (0.42) NR1H2ESR2NPC1RAB9AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 PDK2 4424/4885CYP11B2 4556/4885NR1H2 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.